Accendra Health, Inc (ACH) Fair Value & Analysis
Healthcare · US · Market cap $238M
Accendra Health, Inc
ACH · US
Fair value as of: Jul 14, 2026
From 6 valuation models · updated today
Fair value updated Jul 14, 2026 — revised from $36.42 to $2.21 (−93.9%) since Jun 24, 2026. Share price +1.2% over the past month.
Price vs Fair Value (12 months)
12‑month range $1.91 – $8.99 · fair‑value band $1.27 – $2.21 · the $3.37 price screens above the $2.21 fair value. As of Jul 14, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Accendra Health, Inc (ACH) currently trades at $3.37, while our model-based Fair Value estimate is $2.21 — implying the stock looks roughly 34.4% overvalued today. We read business quality at 33/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Accendra Health, Inc generated revenue of $2.7B at a net margin of -39.8%. Revenue declined 6.8% year over year. Net debt stands at $2.0B. Fundamentals as of Jul 14, 2026
Our scenario range runs from $1.27 (bear case) to $2.21 (bull case); at $3.37, the current price sits above that range. The share trades about 65% below its 52-week high and 83% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside — at -34%, ACH screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 14, 2026. TTM = trailing twelve months.
About the company
Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services. The company also supplies other home medical equipment, patient care product lines including ostomy, wound care and negative pressure wound therapy, urology, incontinence, and other products and services. It serves patients and home health agencies. The company was formerly known as Owens & Minor, Inc. and changed its name to Accendra Health, Inc. in December 2025. Accendra Health, Inc. was founded in 1882 and is based in Glen Allen, Virginia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Accendra Health, Inc reported revenue of $2.8B in FY2025 versus $9.8B in FY2021, a compound −27.1%/yr. Reported net income was −$1.1B in FY2025.
Is ACH fairly valued? → Check now
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 14, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $744.85 | $798.00 | +7% |
| Cencora, Inc COR | $270.32 | $168.24 | -38% |
| Cardinal Health, Inc CAH | $216.30 | $110.75 | -49% |
| Sigma Healthcare Limited SIGGF | $2.35 | $0.7800 | -67% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.34 | ¥34.72 | +112% |
| Henry Schein, Inc HSIC | $76.30 | $53.31 | -30% |
| Galenica AG GALNF | $115.00 | $84.59 | -26% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥20.81 | ¥30.70 | +48% |
| Medipal Holdings MEPDF | $18.35 | $29.88 | +63% |
| Jointown Pharmaceutical Group 600998 | ¥4.79 | ¥9.84 | +105% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Accendra Health, Inc (ACH) undervalued?
What is the fair value of ACH?
What is the quality score of ACH?
What is the revenue of Accendra Health, Inc (ACH)?
What is the net profit margin of ACH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Accendra Health, Inc analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.